plaintiffs may calculate the value of non-monetary terms”); In re Effexor XR Antitrust Litig., No. 11-5479(PGS)(LHG), 2014 WL 4988410, at *19 (D.N.J. Oct. 6, 2014) (“The common use of the term payment is described as something given to discharge a debt or obligation and does not require the payment to be in the form of money.”); Time Ins. Co. v. Astrazeneca AB, 52 F.Supp.3d 705, 710 (E.D.Pa.2014) (“In my opinion, reverse payments deemed anti-competitive pursuant to Actavis may take forms other than cash payments.”); In re Lipitor Antitrust Litig., 46 F.Supp.3d 523, 543 (D.N.J.2014) (finding that Actavis covers situations where “the non-monetary payment [can] be converted to a reliable estimate of its monetary value”); In re Niaspan Antitrust Litig., 42 F.Supp.3d 735, 751 (E.D.Pa.2014) (<HOLDING>); In re Nexium (Esomeprazole) Antitrust Litig.,
holding that it was not essential to an action by a supplier on a payment bond under the miller act that a demand be made on the general contractor for payment  although there was evidence in the case from which it could be found that the materialman looked to the general contractor for payment  since the statute does not require a demand for payment but merely requires written notice of the claim holding that the term reverse payment is not limited to a cash payment holding that  1322c2 refers to the final payment under the original mortgage schedule and not the most recent payment holding that section 72504 barred application of voluntary payment defense to payment of excessive commissions holding that a clause making payment by the owner an express condition precedent to payment by the general contractor to the subcontractor was enforceable